The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to ziprasidone therapy may include headache, postural hypotension, tachycardia and dyskinesia.
Statement B: Compliance Statement B
: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations.
This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.